Jie Shen

机构：Fudan University Shanghai Cancer Center, Minhang District Central Hospital, Nanjing Drum Tower Hospital · ORCID：0000-0003-3157-4640

发表论文 44 篇 · 总被引 178 次 · h-index 6

代表论文

• An eyecare foundation model for clinical assistance: a randomized controlled trial (2025 · Nature Medicine · 被引 44)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 21)
• Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression (2025 · Journal of Translational Medicine · 被引 6)
• Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study (2023 · Cancer Medicine · 被引 6)
• Engineered Mycobacterium smegmatis expressing anti-PD-L1/IL-15 immunocytokine induces and activates specific antitumor immunity (2025 · Journal for ImmunoTherapy of Cancer · 被引 5)
• Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma (2025 · Cancer Immunology Immunotherapy · 被引 5)